Funding for this research was provided by:
Wellcome (107311/Z/15/Z, 207511/Z/17/Z)
National Institute for Health Research (CS_2016_16_007)
Medical Research Council (MR/L001756/1)
Received: 24 November 2019
Accepted: 26 May 2020
First Online: 21 July 2020
Change Date: 12 September 2020
Change Type: Correction
Change Details: An amendment to this paper has been published and can be accessed via the original article.
Ethics approval and consent to participate
: This study was approved by the UK National Research Ethics Service (reference: 10/H0713/51). All participants provided written informed consent.
: Not applicable.
: Dayle Sampson, Thomas Yager, Brian Fox, Leo McHugh, Therese Seldon, Antony Rapisarda, Richard B. Brandon, and Krupa Navalkar state that they are present or past employees and/or shareholders of Immunexpress, Inc. In silico discovery of the <i>SeptiCyte™</i> signatures was performed by Immunexpress. The evaluation of the performance of this signature in the prospective ED cohort was conducted entirely by independent investigators at UCL, with no commercial interest in Immunexpress. This includes the design of the inclusion criteria for the cohort study, participant recruitment, clinical data collection and case ascertainment, sample collection, measurement of the RNA signatures and evaluation of the performance of these signatures.